Daily Management: Balancing Your Child's Hormones
At a Glance
Children with STAR deficiency need carefully timed hydrocortisone and, when needed, fludrocortisone and prescribed salt. Doctors adjust treatment using growth, energy, blood pressure, and salt and potassium tests rather than trying to normalize ACTH alone.
Managing Lipoid Congenital Adrenal Hyperplasia (LCAH) requires a precise balance of replacement hormones. Because your child’s body cannot adequately produce its own cortisol or aldosterone, the goal of daily treatment is to mimic the body’s natural rhythms as closely as possible while avoiding the side effects of too much medication [1][2].
Medication Overview Table
| Medicine | Purpose | Routine Timing | What to Do if Missed/Vomited | Who to Call |
|---|---|---|---|---|
| Hydrocortisone | Replaces Cortisol | 3–4 times daily, per clinician | Check sick day plan; may need injection | Clinic / 911 if crisis |
| Fludrocortisone | Replaces Aldosterone | Usually 1–2 times daily | Follow clinician instructions | Clinic |
| Sodium Chloride | Maintains Salt | Exactly as prescribed | Follow clinician instructions | Clinic |
Glucocorticoid Replacement (Hydrocortisone)
The most critical part of daily therapy is replacing cortisol. In children, hydrocortisone is the preferred medication because it is short-acting and less likely to interfere with natural growth than longer-acting steroids [2][3].
- Dosing Schedule: Hydrocortisone is typically given in three or four doses throughout the day to keep hormone levels stable [2][4]. A common strategy is to give the largest dose first thing in the morning [5], though this varies.
- Target Doses: Maintenance doses vary widely based on age, body size (body surface area), residual STAR function, and clinical findings. For example, a classic illustrative range might start around 8 to 10 mg/m²/day, but this is not a universal prescription [2][6]. Never change or withhold hydrocortisone based on a single laboratory value without the endocrine team.
- The Growth Balance: Your doctor will monitor your child’s growth velocity (how fast they are growing) very closely. If the dose is too low, the child may experience low energy or “adrenal crises”; if it is too high, it can lead to weight gain and slowed height growth [2][3].
Mineralocorticoid and Salt Replacement
Because STAR deficiency also affects the body’s ability to balance salt and water, many children—especially those with the classic form—require two additional supplements:
- Fludrocortisone: This medication replaces aldosterone. It helps the kidneys hold onto sodium and get rid of excess potassium [7]. It is usually taken once or twice daily.
- Sodium Chloride (Salt) Supplementation: Infants, in particular, often need liquid salt added to their formula or breast milk because their kidneys are less efficient at processing fludrocortisone [8]. This must be measured exactly as prescribed.
Monitoring Success
Unlike some conditions where one blood test tells the whole story, monitoring LCAH requires looking at several markers together.
- Electrolytes: Frequent blood tests will check levels of sodium and potassium.
- Plasma Renin Activity (PRA): Renin is a hormone that rises when the body is “thirsty” for more salt or mineralocorticoid. In LCAH, doctors often aim for renin levels to be in the upper-normal range, though targets are individualized [7][9].
- Blood Pressure: Regular blood pressure checks help ensure the fludrocortisone dose isn’t causing hypertension (high blood pressure) [9][10].
The “ACTH Trap”
One of the most important things for parents to understand is why ACTH (Adrenocorticotropic Hormone) should not be chased in isolation.
In a healthy body, ACTH tells the adrenals to work. In STAR deficiency, because the adrenals cannot respond adequately, ACTH levels can become very high [11]. ACTH often remains high even when a child is well treated [11][12].
It is a common mistake to think hydrocortisone doses must be increased simply to bring the ACTH level down. Pursuing a “normal” ACTH level often results in giving the child far more steroid than their body needs, which can lead to stunted growth, unhealthy weight gain, and weakened bones [2][13].
Instead of changing doses based on a single ACTH number, your care team will interpret it alongside medication adherence, dose timing, energy levels, growth charts, electrolytes, and renin [8][14]. Your role is to provide the consistent, timed dosing that keeps these levels stable day-to-day.
Common questions in this guide
What daily medicines are used for children with STAR deficiency?
Why is hydrocortisone divided into several doses each day?
What should I do if my child misses or vomits a hydrocortisone dose?
Can ACTH remain high even when LCAH treatment is working?
How do doctors know whether hormone replacement is properly balanced?
What are signs that my child may be receiving too much or too little hydrocortisone?
Get notified when new evidence is published on Congenital lipoid adrenal hyperplasia due to STAR deficency.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (14)
- 1
Adrenal Crisis in an Adult Patient With Lipoid Congenital Adrenal Hyperplasia due to STAR Protein Mutation.
Zavgorodneva Z, Kaljevic M, Chen K
AACE endocrinology and diabetes 2026; (13(5)):788-791 doi:10.1016/j.aed.2026.04.016.
PMID: 42978993 - 2
Treatment and Follow-up of Non-stress Adrenal Insufficiency
Buğrul F, Özcan Murat N
Journal of clinical research in pediatric endocrinology 2025; (17(Suppl 1)):93-101 doi:10.4274/jcrpe.galenos.2024.2024-6-23-S.
PMID: 39713906 - 3
Growth alterations in rare forms of primary adrenal insufficiency: a neglected issue in paediatric endocrinology.
Ferrigno R, Cioffi D, Pellino V, et al.
Endocrine 2023; (80(1)):1-9 doi:10.1007/s12020-022-03236-z.
PMID: 36309634 - 4
Hydrocortisone dosing in children with classic congenital adrenal hyperplasia: results of the German/Austrian registry.
Hoyer-Kuhn H, Huebner A, Richter-Unruh A, et al.
Endocrine connections 2021; (10(5)):561-569.
PMID: 33909597 - 5
Pharmacokinetic/Pharmacodynamic Evaluation of Hydrocortisone Therapy in Pediatric Patients with Congenital Adrenal Hyperplasia.
Melin J, Parra-Guillen ZP, Michelet R, et al.
The Journal of clinical endocrinology and metabolism 2020; (105(3)) doi:10.1210/clinem/dgaa071.
PMID: 32052005 - 6
International practice of corticosteroid replacement therapy in congenital adrenal hyperplasia: data from the I-CAH registry.
Bacila I, Freeman N, Daniel E, et al.
European journal of endocrinology 2021; (184(4)):553-563.
PMID: 33460392 - 7
Primary Adrenal Insufficiency: Managing Mineralocorticoid Replacement Therapy.
Esposito D, Pasquali D, Johannsson G
The Journal of clinical endocrinology and metabolism 2018; (103(2)):376-387 doi:10.1210/jc.2017-01928.
PMID: 29156052 - 8
Two siblings with lipoid congenital adrenal hyperplasia: first reported case in Serbia and literature review.
Jesic MD, Kovacevic S, Zdravkovic V, et al.
Frontiers in endocrinology 2026; (17()):1912249 doi:10.3389/fendo.2026.1912249.
PMID: 42688021 - 9
Plasma Renin Measurements are Unrelated to Mineralocorticoid Replacement Dose in Patients With Primary Adrenal Insufficiency.
Pofi R, Prete A, Thornton-Jones V, et al.
The Journal of clinical endocrinology and metabolism 2020; (105(1)) doi:10.1210/clinem/dgz055.
PMID: 31613957 - 10
Renin and electrolytes indicate the mineralocorticoid activity of fludrocortisone: a 6 year study in primary adrenal insufficiency.
Ceccato F, Torchio M, Tizianel I, et al.
Journal of endocrinological investigation 2023; (46(1)):111-122 doi:10.1007/s40618-022-01889-1.
PMID: 35947299 - 11
A case report of pedigree of a homozygous mutation of the steroidogenic acute regulatory protein causing lipoid congenital adrenal hyperplasia.
Fu R, Lu L, Jiang J, et al.
Medicine 2017; (96(21)):e6994 doi:10.1097/MD.0000000000006994.
PMID: 28538409 - 12
Long-term follow-up in a Chinese child with congenital lipoid adrenal hyperplasia due to a StAR gene mutation.
Zhao X, Su Z, Liu X, et al.
BMC endocrine disorders 2018; (18(1)):78 doi:10.1186/s12902-018-0307-6.
PMID: 30400872 - 13
The Complex Spectrum of 11β-Hydroxylase Deficiency: A Case of Precocious Puberty, Hypertension, and Testicular Adrenal Rest Tumors (TARTs).
Mangam NB, Deb P, Nalla S, et al.
Cureus 2025; (17(10)):e94192 doi:10.7759/cureus.94192.
PMID: 41209875 - 14
A Prospective Study of Children Aged 0-8 Years with CAH and Adrenal Insufficiency Treated with Hydrocortisone Granules.
Neumann U, Braune K, Whitaker MJ, et al.
The Journal of clinical endocrinology and metabolism 2021; (106(3)):e1433-e1440 doi:10.1210/clinem/dgaa626.
PMID: 32888021
This page is for informational purposes only and does not constitute medical advice. Your child's pediatric endocrinology team must set medication doses, sick-day instructions, and monitoring targets.